ArticleHemaSphere2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.
Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02751255 (A Phase 1 and Phase 2 Study of Daratumumab in Combination With All-trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1 and Phase 2 Study of Daratumumab in Combination With All-trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study.Nature communications · 2026Trial
- Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.BMJ (Clinical research ed.) · 2025Trial
- Trial
- Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias.Annals of hematology · 2026Article
- CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target.Leukemia · 2026Article
- Natural killer cells from patients relapsing on daratumumab therapy express an exhausted-associated phenotype.Clinical hematology international · 2026Article
- Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma.Blood advances · 2025Article
- Article
- Article
- Optimization of lentiviral delivery of barcoded anti-CD20 chimeric antigen receptors into rhesus macaque and human natural killer cells.Molecular therapy. Methods & clinical development · 2025Article
- Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacyBrain, behavior, & immunity - health · 2024Article
- Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.Experimental hematology & oncology · 2024Review
- Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.HemaSphere · 2024Article
- High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.Cancer immunology research · 2024Article
- Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.Blood cancer journal · 2024Article
- Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma.Journal for immunotherapy of cancer · 2024Article
- Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma.Frontiers in cell and developmental biology · 2024Review
- Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.Cancer medicine · 2023Review
- T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions.EJHaem · 2023Review
- Molecular and immunological mechanisms of clonal evolution in multiple myeloma.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The CD38-targeting antibody daratumumab has marked activity in multiple myeloma (MM). Natural killer (NK) cells play an important role during daratumumab therapy by mediating antibody-dependent cellular cytotoxicity via their FcγRIII receptor (CD16), but they are also rapidly decreased following initiation of daratumumab treatment. We characterized the NK cell phenotype at baseline and during daratumumab monotherapy by flow cytometry and cytometry by time of flight to assess its impact on response and development of resistance (DARA-ATRA study; NCT02751255). At baseline, nonresponding patients had a significantly lower proportion of CD16
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.